Carregant...

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating mutations within the epidermal growth factor receptor (EGFR) frequently derive significant clinical and radiographic benefits from treatment with EGFR tyrosine kinase inhibitors (TKIs). As such, prospective identificat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Westover, D, Zugazagoitia, J, Cho, B C, Lovly, C M, Paz-Ares, L
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6454547/
https://ncbi.nlm.nih.gov/pubmed/29462254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx703
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!